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Abstract
Background: Growing evidence suggests that the majority of tumors are organized hierarchically, comprising a 
population of tumor-initiating, or cancer stem cells (CSCs) responsible for tumor development, maintenance and 
resistance to drugs. Previously we have shown that the CD133high/CD44high fraction of colon cancer cells is different 
from their bulk counterparts at the functional, morphological and genomic levels. In contrast to the majority of colon 
cancer cells expressing moderate levels of CD133, CD44 and CD166, cells with a high combined expression of CD133 
and CD44 possessed several characteristic stem cell features, including profound self-renewal capacity in vivo and in 
vitro, and the ability to give rise to different cell phenotypes. The present study was undertaken for two aims: a) to 
determine stem cell-related genomic characteristics of floating 3D multicellular spheroids induced by CD133high/
CD44high colon cancer cells; and b) to evaluate CSC-specific alterations induced by new-generation taxoid SB-T-1214.
Results: Selected CSC phenotype was isolated from three independent invasive colon cancer cell lines, HCT116, HT29 
and DLD-1. A stem cell-specific PCR array assay (SABiosciences) revealed that colonospheres induced by purified 
CD133high/CD44high expressing cells display profound up-regulation of stem cell-related genes in comparison with 
their bulk counterparts. The FACS analysis has shown that the 3D colonospheres contained some minority cell 
populations with high levels of expression of Oct4, Sox2, Nanog and c-Myc, which are essential for stem cell 
pluripotency and self-renewal. Single administration of the SB-T-1214 at concentration 100 nM-1 μM for 48 hr not only 
induced growth inhibition and apoptotic cell death in these three types of colon cancer spheroids in 3D culture, but 
also mediated massive inhibition of the stem cell-related genes and significant down-regulation of the pluripotency 
gene expression. PCR array and FACS data were confirmed with western blotting. Importantly, viable cells that survived 
this treatment regimen were no longer able to induce secondary floating spheroids and exhibited significant 
morphological abnormalities.
Conclusions: We report here that a new-generation taxoid SB-T-1214 possesses significant activity against colon 
cancer spheroids induced by and enriched with drug resistant tumorigenic CD133high/CD44high cells and efficiently 
inhibited expression of the majority of stem cell-related genes. Our data indicates that the previously observed long-
term efficacy of SB-T-1214 against drug resistant colon tumors in vivo may be explained by the down-regulation of 
multiple stem cell-related genes in the tumorigenic cell population, in addition to its known efficacy as a mitotic 
poison against proliferating cancer cells.
Background
With a worldwide cumulative incidence rate of 9.4%, col-
orectal cancer is the second leading cause of cancer
deaths when both sexes are combined [1]. Currently, anti-
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cancer drug development has a significantly lower suc-
cess rate compared to other diseases [2], and this ineffec-
tiveness of standard anti-cancer drugs has been
attributed to the existence of relatively rare, highly drug
resistant, quiescent or slow proliferating tumor-driving
cells - cancer stem cells (CSCs). After the successful isola-
tion and characterization of CSCs from all major types of
human liquid and solid tumors [reviewed in ref. [3]] it
became evident that CSCs are exclusively endowed with
tumor-initiating capacity in the majority, if not all, cancer
types, and are responsible for tumor sustaining, recur-
rence, metastasis and resistance to treatment. CSCs give
rise to a hierarchy of actively proliferating, but progres-
sively differentiating, tumor cells (committed progeni-
tors), which contribute to the cellular heterogeneity of
human cancers. Many types of CSCs, including tumor-
initiating cells in brain [4,5], kidney [6], liver [7,8], colon
[9,10] and pancreatic [11] carcinomas were isolated and
enriched using the cell surface marker CD133, or promi-
nin-1 [12] alone or in combination with some other
markers. Another commonly used cell surface marker is
CD44 [13-22]. This glycoprotein is involved in many cell-
cell interactions, stemness and tumor development, in
part via β-catenin and Wnt signaling activation of the
CD44 gene transcription [23,24]. It was demonstrated
earlier that the full range of CD44 alternatively spliced
variants is widely expressed in normal and tumor colonic
cells located in the crypt base [25], known as a colonic
stem cell niche. Numerous studies have demonstrated
that both CD133+ and CD44+ cells are highly tolerant to
anti-cancer therapies [21,26-33], and moreover, the num-
ber of CSCs can be significantly increased after treatment
[28,34-38]. The ratio of CD133+  cells correlates with
tumor aggressiveness, histologic grade and clinical out-
come [5,39-42]. Similar data were reported for CD44-
positive cells [21].
Since CSCs are naturally resistant to chemotherapy due
to multiple mechanisms, including their relative quies-
cence, profound capacity for DNA repair, activation of
the ATP-binding cassette (ABC) transporters that efflux
many standard anticancer agents, resistance to apoptosis
and others [43-45], it is conceivable that effective anti-
cancer drugs must be specifically targeted toward CSCs,
not only to bulk tumor cells. Colon cancer is inherently
drug-resistant due to multiple mechanisms that are still
poorly characterized, so both the stem cells and the vari-
ably differentiated cells that comprise the proliferative
pool of the colorectal carcinoma can potentially contrib-
ute to chemotherapy tolerance. The CSCs are biologically
distinct from differentiated normal and cancerous cells;
therefore, the search for therapies that are specific for
CSCs should be focused on differences in gene expression
patterns between these cell types. Previously we have
shown that several new-generation taxoids, which were
developed as an attempt to improve widely used taxane-
based anticancer agents [46], exhibited cytotoxicity 2-3
orders of magnitude higher than commonly used pacli-
taxel and docetaxel against drug resistant breast cancer
cells overexpressing the Pgp efflux pump [47,48]. One of
these taxoids, SB-T-1214, also exhibited high efficiency
against colon cancer in vivo, inducing complete regres-
sion of drug-resistant colon tumor xenografts in all sur-
viving mice with tumor growth delay up to 201 days [49].
Such promising antitumor activity of SB-T-1214 led us to
suggest that this compound can specifically target tumor-
specific CSCs by inhibiting some stemness-related signal-
ing pathways and/or promoting their differentiation.
Since CSC-enriched CD133+ and CD44+ cell populations
are more resistant to conventional therapies than other
more differentiated cells [21,26-33], it was important to
test cytotoxic effects of SB-1214 against these cell pheno-
types. Since CSCs represent a dynamic population with
dual potential, self-renewal versus generation of the com-
mitted progenitors, which eventually will differentiate
into all mature cell phenotypes, the isolated CSCs was
cultured, tested and treated under conditions designed to
retain their "stemness" and preclude differentiation to the
bulk tumor cells. Recent discovery of the possibility to
reprogram adult differentiated epithelial cells into
induced pluripotent stem cells by introduction of several
essential transcription factors (Oct4, Sox2, c-Myc and
Klf4) that determine cell stemness/differentiation state
and regulate stem cell self-renewal [50,51], makes these
genes an important target for anticancer drug develop-
ment. The present study was thus undertaken for two
aims: a) to determine the stem cell-related genomic dif-
ferences between CSC-enriched floating colonospheres
grown from CD133high/CD44high cells in comparison to
their bulk counterparts using three independent colon
cancer cell lines; and b) to evaluate CSC-specific altera-
tions induced by new-generation taxoid SBT-1214.
Results
A new-generation taxoid SB-T-1214 was evaluated for its
efficacy against several drug-resistant human tumor
xenografts, including colon tumors (Pgp+ DLD-1) in
severe combined immune deficient (SCID) mice in our
previous study [49]. The drug was administered intrave-
nously in three doses 3 times using a 3-day regimen (q3d
× 3, on day 5, 8, and 11), starting from day 5 after DLD-1
subcutaneous tumor implantation (results are summa-
rized in Table 1). As anticipated, paclitaxel was ineffective
against this highly drug-resistant (Pgp+) tumor at its
optimal dose (60 mg/kg total dose). In contrast, SB-T-
1214 has shown profound antitumor activity. The best
result was obtained at 60 mg/kg total dose, 20 mg/kg × 3,
wherein complete regression of the DLD-1 tumor was
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>201 days). Systemic toxicity profile has shown that there
was only a 3-5% weight loss during the period of day 15 to
day 20, and the drug was well tolerated by animals. Histo-
pathological analysis of the hematoxylin and eosin
stained tissue sections of the tumor xenografts recovered
from the control (vehicle treated) mice revealed a large
tumor areas with densely packed tumor cells (Figure 1A),
which uniformly expressed membrane-bounded immu-
noreactivity for human epithelial cell adhesion molecule,
hEpCAM (Figure 1B; hEpCAM-FITC; Biosource, CA,
USA). Several small clusters of cells with high levels of
CD133 expression were found predominantly within the
outer areas of the tumors corresponding to the tumor
invasive front (Figure 1C), and scattered CD133+ cells
were detected across the entire tumor areas. Flow cytom-
etry analysis of the dissociated and immunomagnetically
sorted (MACS-hEpCAM) mice tumor xenografts con-
firmed the presence of a minor population (about 4%) of
human cancer cells with high combined expression of the
CD133 and CD44 (Figure 1D). After three consequent
treatments with the SB-T-1214, we observed a complete
reduction in tumor volume (Figure 1E). Residual tissues
showed multiple inflammatory infiltrates and fibrosis
(not shown), and they were negative for human EpCAM
(F) and CD133 (G). Since SB-T-1214-treated mice did not
show any presence of human cells, FACS analysis of the
mice tissues was not performed.
Isolation, purification and propagation of colon CSC 
phenotype
To study the effects of SB-T-1214 specifically targeted to
colon CSCs, we have selected three independent colon
cancer cell lines, including DLD-1, which was used in our
previous in vivo studies of the antitumor activity of SB-T-
1214, and two other highly invasive colon cancer cell
lines, HCT116 and HT29. We have found that the vast
majority (bulk) of all types of cells grown at standard
adherent conditions expressed moderate levels of CD133
and CD44 (Figure 2; A-C). However, all three cell lines
possessed minority cell populations with highest expres-
sion of CD133, which coincided with high expression of
CD44 (CD133high/CD44high; red squares on A-C). Previ-
ously, we have characterized this phenotypic subpopula-
tion in colon and prostate cancers by functional and
genome-wide analysis, and demonstrated that these cells
have profound self-renewing capacity in vivo and in vitro,
Table 1: Antitumor effect of SBT-1214 delivered i.v. to SCID mice bearing PgP+ DLD-1 human colon tumor xenografts.
Treatmenta Sche-dule Total Dose 
(mg/kg)
Dose/inj 
(mg/kg)
Days to 
600 mm3
Pvalueb 
(Control)
Growth Delay 
(days)
Toxicityc Cured Mice 
per groupd
Control 0 0 17 --- --- 0 0/10
Vehicle-tween
Paclitaxel
q3d × 3
q3d × 3
0
60
0
20
16 .405
<.001
-1
8
0
0
0/4
0/5
SB-1214 q3d × 3 30 10 54 <.001 37 0 0/5
SB-1214 q3d × 3 60 20 >201 <.001 >150 0 5/5
SB-1214 q3d × 3 120 40 >201 .001 >150 2 3/5
aTreatment given IV to SCID mice on day 5 after DLD-1 human colon tumor implant, and continued as noted; all drugs formulated in Tween/EtOH
bBased on comparison of each group vs. control using the Cox-Mantel Test
cNumber of animals who either died or lost greater than 20% body weight
dSCID mice with no palpable tumor at end of experiment day 167.
Figure 1 Histopathological, immunohistochemical and FACS 
analyses of the mice tumor xenografts. Tumors recovered from the 
control (vehicle treated; A-D) and SB-T-1214 treated (E-G) mice were 
sectioned and stained with hematoxylin and eosin (A, E), human epi-
thelial adhesion molecule hEpCAM-FITC; B, F) and CD133-FITC (C, G). 
The tissue section from vehicle treated mouse show large area of living 
tumor positive for human EpCAM-FITC (B). Cluster of the CD133-posi-
tive cells from the outer tumor area (C). FACS analysis of the dissociated 
and immunomagnetically sorted for hEpCAM untreated mice tumor 
xenograft shows the presence of the minor population of cancer cells 
with high combined expression of CD133-APC and CD44-PE (dashed 
square; D). Complete loss of the tumor cells (E) and hEpCAM- (F) and 
CD133-positivity (G) after three consequents treatments with SB-T-
1214.Botchkina et al. Molecular Cancer 2010, 9:192
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and 3D spheroids induced by this cell phenotype pos-
sessed stem-like features in contrast to their bulk coun-
terparts [19,20]. Even without additional purification, the
acutely isolated CD133high/CD44high cells derived from all
three colon cancer cell lines possessed relatively high effi-
ciency in forming dense floating multicellular spheroids
in non-adherent cultures with serum-free medium (Fig-
ure 2; A-C), in contrast to their corresponding bulk coun-
terparts, which produced a few loose flat colonies (not
shown). The HCT116 spheroids revealed higher effi-
ciency (one of 66 isolated cells induced dense 3D spheres)
compared to HT29 (one of 175 cells) and DLD-1 (one of
118 cells). Dissociated spheroid cells retained an original
cell phenotype and expressed all the studied commonly
used stem cell surface markers, including CD133, CD44,
CD166,  hEpCAM, CD49b, and CD117 (CD133high/
CD44high population is shown on Figure 2; D-F, dashed
squares). Immunohistochemical analysis revealed a
minority cell population expressing high levels of nuclear
β-catenin (not shown). Induced multicellular spheroids
were further tested for the expression of stem cell-related
genes and CSC-related activity of SB-T-1214 in compari-
son to their bulk counterparts using PCR array assay
(SABiosciences). However, these experiments required
not only enriched CSCs, but also culture conditions
which allow for retaining of the stem-like phenotype dur-
ing drug treatment. Previously, we have found that addi-
tional purification of CD133high/CD44high cell population
by repeated sets of cell sorting followed by culturing at
low cell density on type I collagen in serum-free stem cell
medium led to significantly higher in vivo tumorigenic
potential and sphere forming capacity of this cell pheno-
type [19,20]. In addition, the levels of expression of these
markers and the ratios of CD133high/CD44high cells in
both mice tumor xenografts and colonospheres were also
higher after transplantation of the purified cell popula-
tions. Our observations are in line with recent data show-
ing that type I collagen indeed promotes the expression of
a stem cell-like phenotype in human colorectal cancer
and increases the expression of CD133 [52]. These
approaches were used for growing 3D spheroids enriched
with highly tumorigenic and clonogenic cells to be able to
reveal genomic differences between these relatively rare
cells in comparison to their much more numerous bulk
counterparts. They were also used as target populations
for studying CSC-specific drug effects.
Cytotoxic effects of SB-T-1214 against CSC-enriched colon 
cancer cells
The CSC-specific cytotoxic effects of SB-T-1214 were
studied in two different settings which promote stemness
phenotype: monolayer adherent to type I collagen cul-
tures and three dimensional cultures of floating spher-
oids. In a first setting, the FACS sorted CD133high/
CD44high cells isolated from peritoneal fluid of metastatic
colon cancer patients or from the established colon can-
cer cell lines were plated on the type I collagen-coated
plates and cultured in the MSCB serum-free medium for
1-2 days before treatment. After 48 hours of incubation
with the drug in concentration ranging from 100 nM-1
μM, a majority (89-96%) of all cell types underwent apop-
tosis [Figure 3; shown HCT116 cells (A-C); and perito-
neal wash from metastatic colon cancer patient (D-F)].
Although about 4-11% of cells survived this treatment
regimen, such cells displayed multiple abnormalities,
including a greatly enlarged size (G-I, K), multiple nuclei
(E, G-I), a significant increase in the number of long (J),
and knobby (F, I) projections and severe vacuolization
(K). Many cells displayed a clear sign of the mitotic catas-
trophe (G-I).
Next we have studied the SB-T-1214 cytotoxicity
against colon cancer spheroids induced by CD133high/
CD44high cells in 3D cultures. Administration of 0.1-1 μM
SB-T-1214 for 48 hours induced a loss of integrity of the
Figure 2 The CD133high/CD44high phenotypic cell population has 
high sphere-forming capacity in the three independent colon 
cancer cell lines HCT116, HT29 and DLD-1. Cells grown at standard 
culture conditions possessed the minority phenotypic subpopulations 
with high combined levels of expression of CD133 and CD44 (left pan-
el; outlined by dashed squares). The sphere-forming efficiency of these 
cells was 1 of 66 for HCT116 cell line, 1 of 175 for HT29, and 1 of 118 for 
DLD-1 cell line. In contrast, bulk cancer cells could induce only a few 
loose flat colonies under non-adherent culture conditions. Induced 
spheroids retained original cell phenotypes (right panel).Botchkina et al. Molecular Cancer 2010, 9:192
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floating spheroids (Figure 4, A-C) and apoptosis in more
than 90% of the sphere cells (D, E). The FITC-conjugated
drug revealed efficient penetration into spheroids (C; 30
min exposure). Most importantly, viable cells which sur-
vived this treatment regimen significantly lost the ability
to form secondary spheroids, which indicates that colon
CSC population was critically affected (Figure 4, F). Thus,
1000 of untreated HCT116 primary spheroid cells
induced 125 ± 6 secondary spheroids, HT29 - 75 ± 7, and
DLD-1 gave rise to 93 ± 6 secondary spheroids, whereas
the SB-T-1214-treated dissociated spheroid cells pro-
duced only 1.5 ± 0.3, 4 ± 0.6, and 3 ± 0.4 secondary spher-
oids, correspondently (P < 0.01). After placement on type
I collagen surfaces, cells that survived drug treatment,
displayed profound morphological abnormalities similar
to those described above (Figure 3, G-K)
Alterations in the stemness-related gene expression profile 
induced by SB-T-1214
The CD133high/CD44high cell populations derived from
the three analyzed colon cancer cell lines were character-
ized with the stem cell pathway-specific PCR Array assay
(SABiosciences). Each array contains SYBR Green-based
real-time PCR gene-specific assays for a set of 84 genes.
Using filtering criteria of a 1.5 or greater fold-change in
expression, we have analyzed differentially expressed
genes in these three types of floating colonospheres com-
pared to their bulk differentiated adherent counterparts,
as well as before and after treatment with SB-T-1214. The
most profound differences were observed in HCT116
spheroids grown from CD133high/CD44high cells (Figure 5;
left panel), which is in line with their higher sphere-form-
ing and tumor-initiating capacities. About one-fourth of
the analyzed stem cell-related genes, including Wnt and
Notch pathway genes responsible for self-renew and cell
cycle regulation, were commonly up-regulated in all
types of spheroids, with significantly higher levels of
expression in HCT116 ones. Thus, 6 of 6 analyzed genes
responsible for stem cell self-renewal (SOX1, SOX2,
MYST1, MYST2, NEUROG2 and  HSPA9), and 3 of 5
genes regulating symmetrical/asymmetricasl cell divi-
sion (NOTCH1, NOTCH2 and  PARD6A) were signifi-
cantly up-regulated in the HCT116 CD133/CD44-high
colonospheres compared to their bulk counterparts. The
most significantly up-regulated genes in HT29 spheroids
Figure 3 Cytotoxic effects of SB-T-1214 on colon CSC-enriched 
cell populations grown on type I collagen-coated surfaces. FACS 
sorted CD133high/CD44high cells derived from colon cancer cell lines 
(HCT116 is shown) and peritoneal fluid of patient with metastatic co-
lon cancer were plated for a short time on collagen type I-coated 
plates in the MSCB medium. Although a majority of these cells were 
killed after 48 hours incubation with 100 nM of SB-T-1214, some per-
centage of the cells survived treatment (A-C, D-F). The cells which sur-
vived treatment expressed multiple abnormalities, including greatly 
enlarged size (G-I, K), multiple nuclei (E, G-I), significant increase in the 
number of long (J), and knobby (F, I) projections and severe vacuoliza-
tion (K). A-C: magnification 10×; D-K: magnification 40×.
Figure 4 Cytotoxic effects of the SB-T-1214 against colono-
spheres grown in 3D cultures. Ten day-old colonospheres grown 
from FACS sorted CD133high/CD44high HCT116 cells on the ultra-low at-
tachment 6-well plates (Corning) were treated with 100 nM SB-T-1214 
for 48 hours, then drug-containing medium was replaced with regular 
MSCBM and analyzed after 24 hours. Treatment with drug induced a 
profound loss of sphere integrity (A, C) and apoptosis in the majority of 
the sphere cells (D-E; FACS analysis with the annexin V-FITC and pro-
pidium iodide). The FITC-conjugated drug showed efficient penetra-
tion into spheroid after 30 min of incubation (B). To evaluate possible 
alterations in sphere-forming capacity, control and drug treated spher-
oids/cells were dissociated to a single cell suspension and an equal 
number of viable cells (400 cells) were plated on ULA 6-well plates in 
MSCB medium containing 10% Matrigel. The number of secondary 
spheroids was counted ten days after plating (F).Botchkina et al. Molecular Cancer 2010, 9:192
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were ACAN, ALPI, APC, ASCL2, CCND2, CD3D, CD4,
CD8A, CD8B, COL2A1, COL9A1, DHH, DLL3, DTX1
FGF1, GJA1, S100B, SOX2, T, TERT and WNT1; and in
DLD-1 spheroids - ALDH1A1, ASCL2, CCND2, CD4,
COL1A1, DLL1, DTX1, FGF1, GJA1, IGF1, JAG1, MME,
NCAM1, and NOTCH1.
Importantly, relatively low concentrations of SB-T-1214
(100 nM-1 μM for 24 or 48 hr) induced dramatic down-
regulation of stemness in the majority of stem cell-related
genes in all three types of colonospheres (Figure 5, right
panel). The most significant drug-induced down-regula-
tion of gene expression was detected: 1) in HCT116
colonospheres for SOX1, RPL13A, BMP3, NEUROG2,
GJB1, GJA1, ASCL2, CTNNA1, GDF2, ALPI, S100B,
CD8B1, ACTB, CCND1, FGF1, PARD6A, DVL1, GDF3,
ISL1, CD3D, MME, FGFR1, RB1, BMP1, AIN1,
ALDH1A1, CD8A, PPARD, FZD1, NUMB, ABCG2; 2) in
HT29 colonospheres for ACAN, ALPI, BMP3, CD3D,
CD4, CD8A, CD8B, CDH2, COL2A1, COL9A1, DHH,
DLL1, DLL3, DTX1, FGF1, FGF3, FZD1, GDF2, IGF1,
MME, MYOD, NCAM1, NEUROG2, S100B, SOX2, and
TERT; 3) in DLD-1 colonospheres for CD4, CDH2,
COL1A1, DLL1, DTX1, IGF1, FGF3, FZD1, JAG1, KRT15,
MSX1, NCAM1 and NOTCH1. Of note, many of these
genes were related to the stem cells self-renewal, regula-
tion of symmetric/asymmetric division and pluripotency.
We have found that the colonospheres induced by
HCT116 cells with CD133high/CD44high phenotype con-
t a i n e d  m i n o r i t y  c e l l  p o p u l a t i o n s  w i t h  h i g h  l e v e l s  o f
expression of several markers, which are essential for
pluripotency and self-renewal of embryonic stem cells,
including Oct4, Sox2, Nanog and c-Myc (Figure 6A). To
analyze possible drug-induced alterations in the expres-
sion of these stem cell-specific transcription factors,
which are low in abundance and present in a minority of
colon cancer cell populations, we treated floating spher-
oids with 100 nM of SB-T-1214 for 24 hours to induce
such alterations, but avoid profound cell death. Impor-
tantly, both FACS and western blot analyses have shown
that the expression of these key pluripotency markers was
suppressed even after single treatment with relatively low
drug concentration (Figure 6B; western blot analysis is
shown). Off note, we have determined that GAPDH
expression was stable in all cell phenotypes, in contrast to
other housekeeping genes, which is in line with recent
report [53].
Discussion
Increasing evidence indicates that effective anticancer
drugs should target cancer-specific tumor-initiating cells,
which are functionally and morphologically different
from their bulk tumor counterparts. In our previous
studies we found that in several analyzed clinically
aggressive metastatic colon cancer specimens, as well as
in the established colon cancer HCT116 cell line derived
from a poorly-differentiated colonic adenocarcinoma, the
majority of cells expressed low-to-moderated levels of
CD133, CD44 and CD166 [20]. However, FACS analysis
Figure 5 Drug-induced alteration in the stem cell-related gene 
expression profiles (PCR Array assay). A majority of the stemness 
genes were up-regulated in floating spheroids grown from CD133high/
CD44high cells derived from HCT116, HT29 and DLD-1 cell lines in com-
parison with their corresponding bulk counterparts (left panel). Treat-
ment of colonospheres with 100 nM SB-T-1214 induced significant 
down-regulation of a majority of the stemness genes (treated colono-
spheres were analyzed compared to untreated ones).
Figure 6 Drug-induced alterations in the expression of the mark-
ers of pluripotency. FACS analysis shows the presence of minor sub-
populations of colon cancer cells within the 3D spheroids induced by 
CD133high/CD44high cells (A), which express the three key pluripotency 
genes (Sox2, Oct4, and c-Myc). Western blot analysis shows the SB-T-
1214-induced changes in the levels of protein expression of these 
pluripotency markers (B). Untreated spheroids (Con 1 and Cont 2); 
treated with drug (SB 1 and SB 2).Botchkina et al. Molecular Cancer 2010, 9:192
http://www.molecular-cancer.com/content/9/1/192
Page 7 of 12
clearly showed the presence of the minority cell popula-
tion wit h highest leve ls of c ombined e xpression of the
CD133 and CD44. In contrast to the major bulk cell pop-
ulation, CD133high/CD44high  phenotype possessed high
tumorigenic and clonogenic capacities after serial trans-
plantations of the low cell numbers, and was able to pro-
duce cells of all the original phenotypes, showing
characteristic stem cell plasticity [54]. Original cell phe-
notypes were retained in both mice tumor xenografts and
floating colonospheres induced by CD133high/CD44high
cells, suggesting that they represent the tumor-initiating,
or colon CSCs in a HCT116 cell line. Moreover, both
mice tumors and spheroids induced by highly purified
CSCs contain higher ratios of cells with original trans-
planted phenotypes compared to original sources, which
is in line with other studies [55]. Genome-wide gene
expression analysis with the Affymetrix DNA microarray
assay revealed that in a CD133high/CD44high cell popula-
tion, many genes related to drug resistance and stemness,
including  N O T C H ,  S h h ,  W n t ,  O c t 4 , were significantly
upregulated compared to their bulk counterparts [20]. In
the present study we further characterized this colon
CSC phenotype using pathway-specific gene expression
profiling with PCR Array assay (SABiosciences) in the
three independent colon cancer cell lines, HCT116,
HT29 and DLD-1. We have found that CD133high/
CD44high cell phenotype was present in all these cell lines,
possessed relatively high sphere-forming capacity, and
induced spheroids which expressed upregulated levels of
the majority of stem cell-related genes compared to their
differentiated counterparts. However, HCT116 cell popu-
lations revealed significantly higher expression of the
stemness genes and higher sphere-forming potential
compared to HT29 and DLD-1.
There is accumulating knowledge that tumor-initiating
cells in metastatic colon cancer may not be demarcated
solely by the expression of CD133 [18,56]. Although both
CD44 and CD133 were reported as putative markers for
many cancer-specific CSCs, including colorectal cancer
(described in Introduction), it remains to be resolved
whether they are of equal functional importance and
what are their interrelationships. A recent study has dem-
onstrated the unique role of CD133 in the normal and
malignant colon, showing that CD133+ normal stem cells
at the base of crypts in the adult intestine (a stem cell
niche) not only generate the entire intestinal epithelium,
b u t  g i v e  r i s e  t o  a l l  t h e  n e o p l a s t i c  c e l l s  i n  m i c e  c o l o n
tumors [57]. It was shown that the proportion of CD133+
cells in colon cancer metastases is higher than in primary
tumors [58], which reflects the well known fact that met-
astatic lesions are more resistant to treatment. However,
another study has shown that only a knockdown of CD44,
but not CD133, strongly prevented clonal formation and
inhibited tumorigenicity in mice xenograft model [59].
Authors reported that CD44+ did not colocalize with
CD133+  cells within colorectal cancer. Similar results
reported by Horst and colleagues showed that the expres-
sion of CD133 correlates with that of CD166, while both
do not correlate with CD44 [60]. However, this data con-
tradicts multiple reports which not only show colocaliza-
tion of the CD133 and CD44 in several types of human
cancer [13,17-20,61], but also suggest their combined
expression as the best CSC marker [18,61]. Such inconsis-
tency may be due to the high heterogeneity of clinical
specimens, diversity of the experimental approaches, and
lack of the specific CSC markers.
Therefore, we have selected the CD133high/CD44high
cell phenotype to study CSC-targeted activity of a new-
generation taxoid, SB-T-1214 in three independent colon
cancer cell lines. Given that this compound led to com-
plete remission in in vivo colon cancer xenograft model
(Pgp+ DLD-1), we hypothesized that it could modulate
some stemness genes/signaling pathways. The traditional
in vitro model, the monolayer of the bulk tumor cells,
poorly represents normal physiological conditions and
has limited relevance to the hierarchically organized in
vivo tumors. In particular, this model is not optimal for
stem cell-based studies, because even highly purified
CSCs can undergo relatively fast differentiation after
being placed in standard adherent cultures with serum-
containing medium, and therefore, observed drug
responses will be related to the bulk tumor cells, not
CSCs. However, in our previous studies we have found
t h a t  s h o rt -t e r m  c u l t u r i n g  o f  r e pe a t e d l y  s o r t e d  c e l l s  o n
type I collagen-coated surfaces in serum-free stem cell
medium led not only to the retaining, but to significant
increase of the ratios of the tumor-initiating cell pheno-
types [19,20]. This data is in line with a recent study
showing that human colorectal carcinoma cells grown on
type I collagen in serum-free medium undergo an epithe-
lial-mesenchymal-like transition and downregulation of
E-cadherin and β-catenin at cell-cell junctions [52].
Authors have found that collagen type I inhibited cell dif-
ferentiation, increased clonogenicity and promoted
expression of CD133 and Bmi1, indicating that it pro-
moted expression of a stem cell-like phenotype in colon
cancer cells. In this context, culturing the adherent to a
type I collagen CSC-enriched cell population in a serum-
free stem cell medium can provide a useful tool for the
preliminary evaluation of the CSC-focused drug
responses. However, altered cell-to-cell and cell-to-
matrix contacts in monolayer cell cultures can affect their
signal transduction pathways and response to treatment
[62-65]; therefore, we studied the SB-T-1214 cytotoxicity
using an alternative model: free-floating colon cancer
spheroids induced by the purified colon cancer tumorige-
nioc cell phenotypes. A three-dimensional model of can-Botchkina et al. Molecular Cancer 2010, 9:192
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cer spheroids was established by Sutherland and
colleagues [66,67] more than three decades before the
discovery of CSCs in human cancers. It is now well docu-
mented that this model is more closely related to original
tumors with respect to cell morphology, metabolic and
proliferative gradients, oxygen and drug penetration and
cell-cell junctions compared to the traditional cancer cell
monolayers [66-70]. In addition, cancer spheroids are
organized hierarchically, similarly to the in vivo tumors,
containing a relatively small population of the tumori-
genic cells and a large spectrum of their progenitors and
differentiated cells, which comprise a bulk mass of the
tumor or spheroid [70-72]. Spheroid cultures favor the
proliferation of undifferentiated cells and can be passaged
for many generations, reflecting the fact that they contain
a population of cells with profound self-renewal capacity.
We have shown that both mice tumor xenografts and 3D
spheroids induced by more purified CD133high/CD44high
cells contained much higher ratios of cells with the origi-
nal phenotype, and possessed higher tumorigenic and
clonogenic potentials [19,20]. Similar findings were
reported for metastatic breast cancer cells [73] and pros-
tate cancer cells lines [16]. Many of the commonly used
anti-cancer drugs induce about 20-fold lower cytotoxicity
against 3D cancer spheroids compared to monolayer cul-
tures [74], and exhibit chemoresistance which recapitu-
lates this resistant phenotype in vivo [39,62,74-78]. In this
context, SB-T-1214 revealed promising cytotoxicity
against CSC-induced floating colon spheroids. In con-
trast to earlier studies on 3D cell cultures, which were
usually limited to the relatively short-term gross evalua-
tion of the inhibition of spheroid growth and apoptosis,
we have analyzed specific stem cell-related responses.
Thus, using a stem cell-focused PCR array assay we have
found that single treatment of the 3D spheroids induced
by CD133high/CD44high  cell populations with relatively
low concentrations of the SB-T-1214 resulted not only in
significant down-regulation of the majority of stem cell-
related genes, but more importantly, led to a dramatic
reduction of their sphere-forming capacity. In addition,
the expression of several key regulators of pluripotency of
the embryonic stem cells, Oct-4, Sox-2, Nanog, Lin-28
and c-Myc, was also inhibited after single treatment with
100 nM of SB-T-1214 for 48 hours. The synergistic action
of these tissue-specific transcription factors is a pivotal
mechanism for determining cellular phenotypes and self-
renewal of embryonic stem cells. Thus, the introduction
of four genes (Oct-3/4, SOX2, c-Myc, and Klf4) into adult
fibroblasts can transform them into pluripotent stem
cells [50,51]. It has been demonstrated later that Oct-3/4
and SOX2 are crucial transcriptional regulators whose
absence makes induction of pluripotency impossible, and
additional genes, including Klf4, c-Myc, Nanog and LIN-
28 are important for the induction efficiency [79]. There
is growing data that the pluripotency markers are also
expressed by CSCs. Thus, the CD133-positive cells iso-
lated from lung cancer tissues possessed the characteris-
tics of stem-like cells and malignant tumors and
expressed Oct4 [80], which was linked to chemo- and
radioresistant properties in lung cancer-derived CD133+
cells. Expression of Oct3/4 and Sox2 was also associated
with an unfavorable clinical outcome [81]. Of interest,
down-regulation of Lin-28 can lead to the rapid produc-
tion of the mature Let-7 g miRNAs, which are required
for cell differentiation [82]. Therefore, significantly
decreased levels of expression of stem cell-related genes
in general, and shut-down of several major players,
including Oct-4, Sox-2, c-Myc and Lin-28 after treatment
with SB-T-1214 is promising, because it most likely
means that treated CSCs in colonospheres were pro-
moted to a more differentiated state. This data is impor-
tant in the light of growing evidence indicating that
standard anti-cancer therapies often promote self-
renewal of tumor-initiating cells and further resistance to
treatment [28-30]. CSC resistance to treatment may be
due to several mechanisms, including overactivated ABC
transporters, high capacity for DNA repair and activated
anti-apoptotic machinery [43-45]. It was recently demon-
strated that treatment with 5-FU and oxaliplatin, a stan-
dard therapy for metastatic colon cancer, induced up to
30-fold enrichment of CD133+ and up to 2-fold enrich-
ment of CD44+ cells in HT29 cell line [31]. This data is in
line with our observation that after a single treatment
with 100 μM Paclitaxel for 24 hr, the clonogenic potential
of the dissociated HT29 and DLD-1 spheres cells was sig-
nificantly increased, so we can assume that post-treat-
ment spheroids contained a higher proportion of putative
colon CSCs compared to untreated spheroids. Since we
have studied the SB-T-1214 induced alterations in the
stemness gene expression profiles using total cell lysates
(equal amounts of the total RNA for PCR arrays and total
protein for western blot analyses), the significant inhibi-
tion of the stem cell-related genes induced by SB-T-1214
is promising.
Conclusions
In conclusion, we report here that a new-generation tax-
oid, SB-T-1214, possesses significant activity against 3D
colon cancer spheroids induced by and enriched with
drug resistant tumorigenic CD133high/CD44high cell pop-
ulations, and efficiently inhibits the expression of a
majority of stem cell-related genes, including several key
regulators of pluripotency and self-renewal of embryonic
stem cells. Therefore, our data indicates that the long-
term efficacy of SB-T-1214 against drug resistant colon
tumors in vivo [49,83] may be explained by down-regula-
tion of multiple stem cell-related genes in tumorigenic
cell populations, in addition to known efficacy of taxoidsBotchkina et al. Molecular Cancer 2010, 9:192
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as a mitotic poisons due to their binding to microtubules
[84] in the proliferating pool of cancer cells. These find-
ings should be further tested across a large series of clini-
cal specimens of primary and metastatic lesions of colon
cancer.
Methods
Cells and Culture systems
Standard HCT116 cells derived from a poorly-differenti-
ated human colonic adenocarcinoma (ATCC) were main-
tained at SBU Cell Culture Facility. Before sorting, cells
were grown in standard conditions (DMEM with 10%
FCS, on uncoated flasks or dishes) at 50-75% confluency.
Isolated candidate CSC phenotypic subpopulations of
colon cancer cells were counted, resuspended in a serum-
free Mesenchymal stem cell medium (MSCBM; Lonza,
Walkersville, MD) and cultured in two different settings:
either as adherent to a type I collagen (Biocoat; Becton
Dickenson, Bedford, MA), or as free-floating spheroids.
CSC Purification and Abs
Cells were labeled with one or several markers conjugated
with different fluorescent dyes, including anti-human
CD133/2-APC (clone 293C3; Miltenyi Biotec, CA, USA);
CD166-PE (clone 105902; R&D Systems, MN, USA);
CD44-FITC (clone F10-44-2), CD44-PE (clone F10-44-2;
Invitrogen/Biosources, USA); CD44v6-FITC (clone 2F10;
R&D Systems, USA), hEpCAM-FITC (Biosource, CA,
USA). Antibodies were diluted in buffer containing 5%
BSA, 1 mM EDTA and 15-20% blocking reagent (Miltenyi
Biotec, CA, USA) to inhibit unspecific binding to non-
target cells. After 15 min incubation at 4°C, stained cells
were sorted with multiparametric flow cytometry with
BD FACS Aria cell sorter (Becton Dickinson, CA) in ster-
ile conditions.
For  immunohistochemical analysis hEpCAM-FITC
(Biosource, CA, USA), biotin-conjugated anti-human
CD133 as primary Abs (Miltenyi Biotec, CA, USA) and
streptavidin-FITC (BD Pharmingen, USA) as a secondary
Abs were used.
Generation of floating multucellular spheroids
Four hunderd cells of particular phenotype were seeded
on each well of the Ultra-Low Attachment (ULA) 6-well
plate (Corning, Lowell, MA) in serum-free MSCB
medium containing 10-25% Matrigel matrix (BD Biosci-
ences) and examined after 1 week of culturing under
standard conditions. Fresh medium was added after one
week of culturing, every third day.
Sphere propagation
After initial culturing during 1-2 weeks on ULA plates,
primary spheres were gently disaggregated by repeated
pipetting and transferred into ULA flasks for further
propagation and maintenance.
Sphere formation assay
Clonogenic potential of different phenotypic subpopula-
tions was determined before and after treatment with SB-
T-1214. Cells were counted, resuspended in MSCBM/
Matrigel and plated on 48-well plates at a final count of
300 cells per well. One to two weeks after initiation, the
plates were inspected for colony (sphere) growth, the
number of colonies within each well was quantified by
phase contrast microscopy and representative fields were
photographed.
Isolation of the CSC populations from peritoneal wash
of colon cancer patients and solid tumors, as well as
induction of the mouse tumor xenografts, were carried
out as we described elsewhere [20].
Drug Treatment
In vivo cytotoxicity
All experiments involving the use of animals were per-
formed in accordance with SBU institutional animal wel-
fare guidelines. Initially, the SB-T-1214 was evaluated for
its efficacy against a drug-resistant human colon tumor
xenograft (Pgp+) DLD-1 in severe combined immune
deficient mice (SCID). Taxoid was administered intrave-
nously at three doses 3 times using 3 day regimens (q3d ×
3, on day 5, 8, and 11), starting from day 5 after DLD-1
subcutaneous tumor implantation.
Cell death
was analyzed with flow cytometry using either Annexin
V/PI staining (BD PharMingen) or Live/Dead assay (Bio-
Vision, CA) as recommended by the manufacturers.
In vitro cytotoxicity
was studied in two settings: a) using adherent type-I col-
lagen monolayer cultures of freshly isolated CD133high/
CD44high cells; and b) three-dimensional cultures of float-
ing multicellular spheroids induced by CD133high/
CD44high and CD133-negative cells.
Adherent to type I collagen cultures
The CD133high/CD44high cells (4-5 × 103 cells/well were
seeded onto the type I collagen-coated 6-well plates, and
the experiments were initiated 24 h later, upon sub-con-
fluency. The regular MSCB medium was replaced with
treatment media containing SB-T-1214 at selected con-
centrations (0.001-0.1 μg/ml). Treatment media was
removed 24 hr later, followed by washing with regular
MSCBM and dissociation of cells with an Enzyme-free
dissociating reagent (Chemicon International). Upon ter-
mination (48 hr from start), cell viability and cell death
was analyzed through flow cytometry.
3D culture
Cytotoxicity studies were carried out when floating
spheroids induced by different cell phenotypes reached
about 400-500 μm in diameter. Spheres were resus-
pended in the drug-containing MSCBM (0.01-0.1 μg/ml)Botchkina et al. Molecular Cancer 2010, 9:192
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and either plated on ULA 48-well plates (5-10 spheres/
well) for microscopy or remained in ULA flasks if a larger
number of sphere cells was required for FACS, PCR array,
western blot and other analyses. After treatment with the
drug for 48 hours, spheroids/cells were rinsed twice in
PBS, centrifuged for 5 min at 1,000 rpm, and incubated in
regular MSCBM for 24 hr. Then, rinsed spheroids/cells
w e r e  d i s s o c i a t e d  w i t h  a n  E n z y m e - f r e e  d i s s o c i a t i n g
reagent and single cell suspensions were further analyzed.
PCR ArrayAssay
Stem cell-specific gene expression profiles were studied
with the PCR Array assay (SABiosciences, CA) in accor-
dance with the manufacturer's recommendations. Briefly,
total RNA was isolated from different cell populations or
whole floating spheroids using PARIS kit (Ambion). Up
to 1 μg of total RNA was treated with DNase and cDNA
was prepared using RT2 First Strand kit. For each analysis,
pairs of the test and control cDNA samples were mixed
with RT2 qPCR Master mix and distributed across the
PCR array 96-well plates, each of which contained 84
stem cell-related probes and control housekeeping genes.
After cycling with real-time PCR (Opticon MJ Research
or ABI 7300, Applied Biosystems), obtained amplification
data (fold-changes in Ct values of all the genes) was ana-
lyzed with SABiosciences software.
Western blotting
Cell pellets were suspended in Lysis Buffer (Active Motif,
CA) and incubated for 10 min on ice on a rocking plat-
form. After brief vortexing, cell lysates were centrifuged
at 4,000 g for 30 min at 4°C. The protein content in the
supernatant was determined by a Bradford method, and
equivalent amounts of total proteins (10 μg) were
resolved on 10% SDS-PAGE gel. After transferring to a
polyvinylidene fluoride membrane, levels of various pro-
teins were determined by Western blot analysis using
antibodies specific for Oct4, Sox2, Nanog, Lin-28, c-Myc,
GAPDH and β-actin, respectively (1:500 dilution, 4°C,
overnight). Following incubation with peroxidase-conju-
gated secondary Abs (anti-rabbit IgG; ECL, UK) for 1 hr
at 25°C, blots were developed using the enhanced chemi-
luminesens (ECL) reagents. Alternatively, the blots were
washed three times with PBST and incubated with Alex-
aFluor 680-conjugated goat anti-rabbit secondary anti-
body (Invitrogen) for 1 hr. Blots were then washed three
times with PBST, twice with water, and the image cap-
tured on an Odyssey Infrared Imaging System (Li-Cor
Biosciences).
Statistical analysis
The statistical significance of differences was determined
using Student's t-test. P < 0.05 was considered statistically
significant.
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